VISEN Pharmaceuticals AI Stock Analysis
Want to see HK:2561 full AI Analyst Report?
VISEN Pharmaceuticals (2561) AI Stock Analysis
VISEN Pharmaceuticals
(HKEX:2561)
The score is primarily constrained by substantial ongoing losses and heavy cash burn, despite improving revenue and a relatively solid balance sheet. Bearish technical positioning and a negative P/E ratio further weaken the outlook; the oversold indicators provide only limited potential support.
VISEN Pharmaceuticals (2561) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.37B
- Dividend Yield
- ―
- Average Volume (3M)
- 10.30K
- Price to Earnings (P/E)
- -4.8
- Beta (1Y)
- 0.87
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 82
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
VISEN Pharmaceuticals Business Overview & Revenue Model
Company Description
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-wee...
VISEN Pharmaceuticals Financial Statement Overview
Summary
Revenue is beginning to ramp, and the company retains a substantial equity base with moderate leverage. However, persistent large losses and approximately HKD 458M of TTM operating cash burn materially weaken the financial profile.
Income Statement
38NegativeBalance Sheet
60NeutralCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.40M | 160.73K | 2.78M | -1.67M | 0 | 0 |
| Gross Profit | 3.78M | 18.51K | 2.78M | -1.67M | -2.30M | -5.66M |
| EBITDA | -233.08M | -236.66M | -177.62M | -242.26M | -280.95M | -444.27M |
| Net Income | -239.50M | -246.86M | -182.24M | -249.57M | -288.97M | -486.18M |
Balance Sheet | ||||||
| Total Assets | 887.16M | 977.72M | 293.82M | 443.80M | 741.27M | 928.71M |
| Cash, Cash Equivalents and Short-Term Investments | 505.81M | 632.92M | 203.59M | 347.78M | 626.46M | 881.06M |
| Total Debt | 176.71M | 177.06M | 2.36M | 3.65M | 6.00M | 11.14M |
| Total Liabilities | 215.91M | 215.34M | 52.55M | 52.92M | 88.67M | 82.24M |
| Stockholders Equity | 671.25M | 762.38M | 241.28M | 390.88M | 652.61M | 846.47M |
Cash Flow | ||||||
| Free Cash Flow | -459.94M | -450.16M | -140.97M | -271.83M | -248.31M | -238.54M |
| Operating Cash Flow | -458.10M | -447.58M | -140.86M | -271.31M | -246.55M | -227.13M |
| Investing Cash Flow | -3.13M | 6.67M | -117.00K | -520.00K | -1.77M | -13.62M |
| Financing Cash Flow | 161.52M | 870.00M | -3.09M | -6.95M | -7.95M | 967.59M |
VISEN Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2561, the sentiment is Negative. The current price of 12.46 is below the 20-day moving average (MA) of 14.39, below the 50-day MA of 17.15, and below the 200-day MA of 22.99, indicating a bearish trend. The MACD of -1.51 indicates Positive momentum. The RSI at 28.95 is Positive, neither overbought nor oversold. The STOCH value of 26.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2561.
VISEN Pharmaceuticals Peers Comparison
Overall Rating
HK:369274.5Outperform
HK:001373Outperform
HK:998956Neutral
HK:255252Neutral
HK:618551Neutral- HK:256142Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:3692 | 75Outperform | HKD 208.73B | 26.59 | 18.26% | 1.41% | 24.97% | 43.23% |
| HK:0013 | 73Outperform | HKD 20.31B | 160.39 | 1.43% | ― | -8.55% | -96.20% |
| HK:9989 | 56Neutral | HKD 14.23B | 69.68 | 1.58% | 4.14% | -1.32% | -50.00% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:2552 | 52Neutral | HKD 2.11B | -18.12 | -10.61% | ― | 83.49% | -110.21% |
| HK:6185 | 51Neutral | HKD 12.32B | 592.43 | 0.60% | ― | 36.09% | ― |
| HK:2561 | 42Neutral | HKD 1.42B | -4.81 | -33.42% | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2561 | VISEN Pharmaceuticals | 12.46 | -20.94 | -62.69% | |
| HK:0013 | HUTCHMED (China) Limited | 23.28 | -0.02 | -0.09% | |
| HK:2552 | Hua Medicine | 2.17 | -1.20 | -35.46% | |
| HK:9989 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H | 4.01 | -1.34 | -24.97% | |
| HK:3692 | Hansoh Pharmaceutical Group Company Limited | 34.42 | -4.40 | -11.33% | |
| HK:6185 | CanSino Biologics, Inc. Class H | 23.78 | -20.40 | -46.17% |
VISEN Pharmaceuticals Corporate Events
VISEN Pharmaceuticals Reshapes Key Governance Roles in Hong Kong
VISEN Pharmaceuticals has announced changes to key corporate governance roles, with company secretary, process agent and authorised representative Ms. Chan Sze Ting resigning due to other work commitments effective 29 October 2026. The board noted th...
VISEN Pharmaceuticals Announces Resignation of Non-Executive Director Sherrie Lynn Glass
VISEN Pharmaceuticals announced that non-executive director Sherrie Lynn Glass has resigned from the board with effect from 5 October 2026 to dedicate more time to her other business commitments. The company emphasized that Glass has no disagreement...
VISEN Pharmaceuticals Details Board and Committee Structure
VISEN Pharmaceuticals has outlined the composition of its board, naming one executive director, four non-executive directors, and three independent non-executive directors, with Mr. Fu Shan serving as chairman. The disclosure underscores the company’...
VISEN Pharmaceuticals Posts Interim 2026 Results and Adjusts Board Committees
VISEN Pharmaceuticals has released its unaudited interim results for the six months ended June 30, 2026, with the figures reviewed by its audit committee and external auditor Ernst & Young in line with Hong Kong listing requirements. The company will...
VISEN Pharmaceuticals Details Board and Committee Structure
VISEN Pharmaceuticals has outlined the composition of its board of directors, detailing the mix of executive, non-executive and independent non-executive members and confirming FU Shan as chairman. The board’s configuration underscores a governance f...
VISEN Pharmaceuticals Sets Board Meeting to Approve 2026 Interim Results
VISEN Pharmaceuticals has scheduled a board meeting for 27 August 2026 to review and approve the group’s interim results for the six months ended 30 June 2026. The meeting will also address other corporate matters, signaling routine financial reporti...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026